CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms

Neuropsychopharmacology

Volumn 34, Issue 8, 2009, Pages 2019-2027

  Juhasz, Gabriella ^a   Chase, Diana ^a   Pegg, Emma ^a   Downey, Darragh ^a   Toth, Zoltan G ^a   Stones, Kathryn ^a   Platt, Hazel ^a   Mekli, Krisztina ^a,b   Payton, Antony ^a   Elliott, Rebecca ^a   Anderson, Ian M ^a   Deakin, J F William ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

CNR1; Depression; Epistasis; Gene environment interaction; Haplotype; Personality

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; DNA; RIMONABANT;

ADULT; AGREEABLENESS; ANHEDONIA; ANXIETY; ARTICLE; BRIEF SYMPTOM INVENTORY; CHROMOSOME 6Q; CNRI GENE; COMORBIDITY; DEPRESSION; ENVIRONMENTAL FACTOR; EPISTASIS; FEMALE; GENE; GENE INTERACTION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HELPLESSNESS; HUMAN; KNOCKOUT MOUSE; LIFE EVENT; LIFE STRESS; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NEGATIVE LIFE EVENT; NEUROSIS; PERSONALITY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOMATOLOGY; UNITED KINGDOM;

ADAPTATION, PSYCHOLOGICAL; ADOLESCENT; ADULT; ANXIETY DISORDERS; BRAIN CHEMISTRY; DEPRESSIVE DISORDER; DNA MUTATIONAL ANALYSIS; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEUROTIC DISORDERS; PERSONALITY; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; QUESTIONNAIRES; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 67449147111     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.19     Document Type: Article

References (69)

1. Ashton CH, Moore PB, Gallagher P, Young AH (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol 19: 293-300.
2. Bagby RM, Bindseil KD, Schuller DR, Rector NA, Young LT, Cooke RG et al (1997). Relationship between the Five-Factor Model of personality and unipolar, bipolar and schizophrenic patients. Psychiatry Res 70: 83-94.
3. Barrero FJ, Ampuero I, Morales B, Vives F, de Dios Luna Del Castillo J, Hoenicka J et al (2005). Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J 5: 135-141.
4. Barrett JC, Fry B, Maller J, Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
5. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K et al (1994). Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 151: 1132-1136.
6. Bienvenu OJ, Samuels JF, Costa PT, Reti IM, Eaton WW, Nestadt G (2004). Anxiety and depressive disorders and the Five-Factor Model of personality: a higher- and lower-order personality trait investigation in a community sample. Depress Anxiety 20: 92-97.
7. Bouchard Jr TJ, McGue M (2003). Genetic and environmental influences on human psychological differences. J Neurobiol 54: 4-45.
8. Brugha T, Bebbington P, Tennant C, Hurry J (1985). The list of threatening experiences: a subset of 12 life event categories with considerable long-term contextual threat. Psychol Med 15: 189-194.
9. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301: 386-389.
10. Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S (2006). Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. Eur J Neurosci 23: 1944-1948.
11. Chavarria-Siles I, Contreras-Rojas J, Hare E, Walss-Bass C, Quezada P, Dassori A et al (2008). Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147B: 279-284.
12. Chen X, Williamson VS, An SS, Hettema JM, Aggen SH, Neale MC et al (2008). Cannabinoid receptor 1 gene association with nicotine dependence. Arch Gen Psychiatry 65: 816-824.
13. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706-1713.
14. Costa Jr PT, McCrae RR (1992). Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory (NEO-FFI) Professional Manual. Psychological Assessment Resources: Odessa, FL.
15. Derogatis L (1993). BSI: Brief Symptom Inventory: Administration, Scoring, and Procedures Manual. National Computer Systems Pearson Inc.: Minneapolis.
16. Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H et al (2008). Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 18: 751-759.
17. Ehlers CL, Slutske WS, Lind PA, Wilhelmsen KC (2007). Association between single nucleotide polymorphisms in the cannabinoid receptor gene (CNR1) and impulsivity in southwest California Indians. Twin Res Hum Genet 10: 805-811.
18. Fanous AH, Kendler KS (2005). Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework. Mol Psychiatry 10: 6-13.
19. Finch JF, Graziano WG (2001). Predicting depression from temperament, personality, and patterns of social relations. J Pers 69: 27-55.
20. Flint J, Shifman S, Munafo M, Mott R (2008). Genetic variants in major depression. Novartis Found Symp 289: 23-32.
21. Freeman B, Smith N, Curtis C, Huckett L, Mill J, Craig IW (2003). DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. Behav Genet 33: 67-72.
22. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al (2002). The structure of haplotype blocks in the human genome. Science 296: 2225-2229.
23. Gorzalka BB, Hill MN, Hillard CJ (2008). Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 32: 1152-1160.
24. Greenberg BD, Li Q, Lucas FR, Hu S, Sirota LA, Benjamin J et al (2000). Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. Am J Med Genet 96: 202-216.
25. Hall W, Solowij N (1998). Adverse effects of cannabis. Lancet 352: 1611-1616.
26. Haller J, Varga B, Ledent C, Barna I, Freund TF (2004a). Contextdependent effects of CBl cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 19: 1906-1912.
27. Haller J, Varga B, Ledent C, Freund TF (2004b). CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15: 299-304.
28. Hamdani N, Tabeze JP, Ramoz N, Ades J, Hamon M, Sarfati Y et al (2008). The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 18: 34-40.
29. Hariri AR, Drabant EM, Weinberger DR (2006). Imaging genetics: perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biol Psychiatry 59: 888-897.
30. Herman AI, Kranzler HR, Cubells JF, Gelernter J, Covault J (2006). Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. Am J Med Genet B Neuropsychiatr Genet 141: 499-503.
31. Hill MN, Gorzalka BB (2005a). Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 16: 333-352.
32. Hill MN, Gorzalka BB (2005b). Pharmacological enhancement of cannabinoid CBl receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 15: 593-599.
33. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG et al (2005). Whole-genome patterns of common DNA variation in three human populations. Science 307: 1072-1079.
34. Hoth KF, Christensen AJ, Ehlers SL, Raichle KA, Lawton WJ (2007). A longitudinal examination of social support, agreeableness and depressive symptoms in chronic kidney disease. J Behav Med 30: 69-76.
35. Jacobs N, Kenis G, Peeters F, Derom C, Vlietinck R, van Os J (2006). Stress-related negative affectivity and genetically altered serotonin transporter function: evidence of synergism in shaping risk of depression. Arch Gen Psychiatry 63: 989-996.
36. John OP, Srivastava S (1999). The Big Five trait taxonomy: history, measurement, and theoretical perspectives. In: Pervin LA, John OP (eds). Handbook of Personality: Theory and Research 2nd edn Guilford Press: New York, pp 102-139.
37. Kendler KS, Gardner CO, Gatz M, Pedersen NL (2007). The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample. Psychol Med 37: 453-462.
38. Kendler KS, Gatz M, Gardner CO, Pedersen NL (2006). Personality and major depression: a Swedish longitudinal, population-based twin study. Arch Gen Psychiatry 63: 1113-1120.
39. Kendler KS, Kuhn J, Prescott CA (2004). The interrelationship of neuroticism, sex, and stressful life events in the prediction of episodes of major depression. Am J Psychiatry 161: 631-636.
40. Khan AA, Jacobson KC, Gardner CO, Prescott CA, Kendler KS (2005). Personality and comorbidity of common psychiatric disorders. Br J Psychiatry 186: 190-196.
41. Lazary J, Lazary A, Gonda X, Benko A, Molnar E, Juhasz G et al (2008). New evidence for the association of the serotonin transporter gene (SLC6A4) haplotypes, threatening life events, and depressive phenotype. Biol Psychiatry 64: 498-504.
42. Leroy S, Griffon N, Bourdel MC, Olie JP, Poirier MF, Krebs MO (2001). Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet 105: 749-752.
43. Lesch KP (2004). Gene-environment interaction and the genetics of depression. J Psychiatry Neurosci 29: 174-184.
44. Levinson DF, Holmans P, Straub RE, Owen MJ, Wildenauer DB, Gejman PV et al (2000). Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and 13q: schizophrenia linkage collaborative group III. Am J Hum Genet 67: 652-663.
45. Liber JM, Faber AW, Treffers PD, Van Loey NE (2008). Coping style, personality and adolescent adjustment 10 years post-burn. Burns 34: 775-782.
46. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG (2007). Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 63: 131-135.
47. Malouff JM, Thorsteinsson EB, Rooke SE, Schutte NS (2007). Alcohol involvement and the Five-Factor Model of personality: a meta-analysis. J Drug Educ 37: 277-294.
48. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002). Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159: 379-387.
49. McCormick RA, Dowd ET, Quirk S, Zegarra JH (1998). The relationship of NEO-PI performance to coping styles, patterns of use, and triggers for use among substance abusers. Addict Behav 23: 497-507.
50. McGue M, Bouchard Jr TJ (1998). Genetic and environmental influences on human behavioral differences. Annu Rev Neurosci 21: 1-24.
51. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
52. Moran P, Coffey C, Mann A, Carlin JB, Patton GC (2006). Dimensional characteristics of DSM-IV personality disorders in a large epidemiological sample. Acta Psychiatr Scand 113: 233-236.
53. O'Brien TB, DeLongis A (1996). The interactional context of problem-, emotion-, and relationship-focused coping: the role of the Big Five personality factors. J Pers 64: 775-813.
54. Reno RM (2004). Personality characterizations of outpatients with schizophrenia, schizophrenia with substance abuse, and primary substance abuse. J Nerv Ment Dis 192: 672-681.
55. Serra G, Fratta W (2007). A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemol Ment Health 3: 25.
56. Shifman S, Bhomra A, Smiley S, Wray NR, James MR, Martin NG et al (2008). A whole genome association study of neuroticism using DNA pooling. Mol Psychiatry 13: 302-312.
57. Snaith RP, Baugh SJ, Clayden AD, Husain A, Sipple MA (1982). The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 141: 518-523.
58. Storey JD, Tibshirani R (2003). Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100: 9440-9445.
59. Terracciano A, Costa Jr PT (2004). Smoking and the Five-Factor Model of personality. Addiction 99: 472-481.
60. Terracciano A, Lockenhoff CE, Crum RM, Bienvenu OJ, Costa Jr PT (2008). Five-Factor Model personality profiles of drug users. BMC Psychiatry 8: 22.
61. Tsai SJ, Wang YC, Hong CJ (2001). Association study between cannabinoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders. Am J Med Genet 105: 219-221.
62. Uher R, McGuffin P (2008). The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol Psychiatry 13: 131-146.
63. Valverde O, Karsak M, Zimmer A (2005). Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handb Exp Pharmacol 168: 117-145.
64. Vinod KY, Hungund BL (2006). Role of the endocannabinoid system in depression and suicide. Trends Pharmacol Sci 27: 539-545.
65. Westfall FH, Young SS (1993). Resampling-Based Multiple Testing: Examples and Methods for P-value Adjustment. Wiley: New York.
66. Widiger TA, Sankis LM (2000). Adult psychopathology: issues and controversies. Annu Rev Psychol 51: 377-404.
67. Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG (2005). A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci 26: 609-617.
68. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D et al (2004). Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 9: 916-931.
69. Zuo L, Kranzler HR, Luo X, Covault J, Gelernter J (2007). CNR1 variation modulates risk for drug and alcohol dependence. Biol Psychiatry 62: 616-626.